What question did this study set out to answer?

To evaluate the safety and effectiveness of sutimlimab in patients with cold agglutinin disease in a real-world setting.

Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real‐World International Experience

View Full Paper

Ask AI

Bookmark

Authors

Real-world analysis shows sutimlimab improves hemolytic anemia in patients with cold agglutinin disease, suggesting effective treatment options.

To evaluate the safety and effectiveness of sutimlimab in patients with cold agglutinin disease in a real-world setting.
Analyzed a cohort of 57 CAD patients treated with sutimlimab.
Monitored hemoglobin levels and hemolytic markers over time.
Assessed response rates and safety profiles, including adverse events.
Examined patient demographics and prior treatments.
Median hemoglobin increased by 2 g/dL within 2 weeks and reached 12 g/dL in 4 weeks.
Objective responses were observed in most patients by week 2; complete responses occurred in about 50% by week 4.
Infections were the most common adverse event, occurring in 23% of cases.
Hemolytic exacerbations were noted in 16% of cases, mainly linked to infections.

Fattizzo et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Real-world analysis shows sutimlimab improves hemolytic anemia in patients with cold agglutinin disease, suggesting effective treatment options.